Sironax, SIR4156, obesity, FORGE-LM, Phase 2 clinical trial, NAMPT activator, semaglutide, NAD+ metabolism, body composition, lean body mass, fat loss, metabolic health,

WALTHAM, Mass. — October 13, 2026 Sironax, a global clinical-stage biotechnology company, announced that its Phase 2 FORGE-LM clinical...